How to get involved

You may be able to join this trial if all of the following apply:

• You have non-small cell lung cancer that is either squamous cell carcinoma or adenocarcinoma.
• You have cancer that has spread outside your lung (stage 3) and you can’t have surgery or radiotherapy with the aim of curing it, or it has spread to another part of your body (stage 4).
• You have had at least one suitable standard treatment and your cancer has continued to grow.
• You have consented and given a sample of your tumour in CRUK’s SMP2.
• You have had a CT or MRI scan in the last 4 weeks that shows an area of cancer that can be measured.
• You are well enough to carry out all of your normal activities, apart from heavy physical work (performance status 0 or 1).
• You are at least 18 years old.
• You have satisfactory blood results.

You cannot join this trial if:

• You have cancer that has spread to your brain or is pressing on your spinal cord, unless this has been treated, is not getting any worse or causing any symptoms, and you haven’t needed to take steroids in the last 4 weeks.
• You have had major chemotherapy, surgery, radiotherapy or any other anti-cancer treatment in the last 4 weeks.
• You have any problems with your digestive system that could affect how you absorb drugs.
• You have had any other cancer in the last 3 years apart from carcinoma in situ of the cervix, or basal cell skin cancer that was successfully treated.
• Are still having side effects from earlier cancer treatment unless they are very mild (except hair loss).
• Have HIV, hepatitis B or hepatitis C.
• Have certain heart problems, which depend on which treatment you might receive.
• Are pregnant or breastfeeding.

The trial is currently aiming to recruit 640 patients. Each cohort will include a maximum of 30 patients and some cohorts may fill up quicker than others if the gene changes that they target are more common in the patient population.

As the trial goes on, the research team may identify other drugs that they think could work for patients with other gene changes. If this happens, new Arms will be added to the trial and the number of patients in the trial will increase.

A group called the Trial Steering Committee will review the trial data at certain points, and may decide to suspend recruitment or remove an Arm or Cohort from the trial if it is not effective.

Stratified Medicine Programme 2 Hospitals:

For a list of hospitals able to recruit patients to SMP2, please go to the Stratified Medicine Hospitals page. 

National Lung Matrix Trial Hospitals:

The following hospitals are able to recruit patients to the National Lung Matrix Trial:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The following hospitals are planning to open in the future:

 

 

 The following hospitals are open as National Lung Matrix Trial ‘Feeder sites’, meaning they can consent patients to another biopsy if there is no tissue available to send for SMP2 testing: